Novogene Co., Ltd. (SHA:688315)
China · Delayed Price · Currency is CNY 13.88
+0.66 (4.99%)
Jul 15, 2026, 3:00 PM CST
Novogene Market Cap
Novogene has a market cap or net worth of 5.35 billion as of July 14, 2026. Its market cap has decreased by -0.30% in one year.
Market Cap
5.35B
Enterprise Value
3.82B
Revenue
2.26B
Ranking
n/a
PE Ratio
33.07
Stock Price
13.88
Market Cap Chart
Since April 13, 2021, Novogene's market cap has decreased from 10.97B to 5.35B, a decrease of -51.17%. That is a compound annual growth rate of -12.75%.
| Date | Market Cap | % Change |
|---|---|---|
| Jul 14, 2026 | 5.35B | -0.45% |
| Dec 31, 2025 | 5.38B | 6.24% |
| Dec 31, 2024 | 5.06B | -47.88% |
| Dec 29, 2023 | 9.71B | -8.02% |
| Dec 30, 2022 | 10.56B | -36.10% |
| Dec 31, 2021 | 16.53B | 50.73% |
| Apr 13, 2021 | Upgrade Pro | Upgrade Pro |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Wuhan Keqian Biology Co.,Ltd | 5.90B |
| Shouyao Holdings (Beijing) Co., LTD. | 5.82B |
| Beijing Konruns Pharmaceutical | 5.42B |
| PharmaResources (Shanghai) | 5.34B |
| Hangzhou Biotest Biotech | 5.08B |
| Zhejiang Wecome Pharmaceutical Company | 4.93B |
| R&G PharmaStudies | 4.91B |
| Xiangxue Pharmaceutical | 4.85B |